본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The Lancet v.391 no.10126 = no.10126, 2018년, pp.1186 - 1196   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

Lai, Zhi-Wei (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Kelly, Ryan (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Winans, Thomas (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Marchena, Ivan (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Shadakshari, Ashwini (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Yu, Julie (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Dawood, Maha (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Garcia, Ricardo (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Tily, Hajra (Division of Rheumatology, State University of New York Upstate Medical University, Syracuse, NY, USA ) ; Francis, Lisa (Division of Rheumatology, State University of New York Upstate Medical Un ) ; Faraone, Stephen V ; Phillips, Paul E ; Perl, Andras ;
  • 초록  

    Summary Background Patients with systemic lupus erythematosus have T-cell dysfunction that has been attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been developed as a medication under the generic designation of sirolimus. We assessed safety, tolerance, and efficacy of sirolimus in a prospective, biomarker-driven, open-label clinical trial. Methods We did a single-arm, open-label, phase 1/2 trial of sirolimus in patients with active systemic lupus erythematosus disease unresponsive to, or intolerant of, conventional medications at the State University of New York Upstate Medical University (Syracuse, NY, USA). Eligible participants (aged ≥18 years) had active systemic lupus erythematosus fulfilling four or more of 11 diagnostic criteria defined by the American College of Rheumatology. We excluded patients with allergy or intolerance to sirolimus, patients with life-threatening manifestations of systemic lupus erythematosus, proteinuria, a urine protein to creatinine ratio higher than 0·5, anaemia, leucopenia, or thrombocytopenia. Patients received oral sirolimus at a starting dose of 2 mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6–15 ng/mL. Patients were treated with sirolimus for 12 months. Safety outcomes included tolerance as assessed by the occurrence of common side-effects. The primary efficacy endpoint was decrease in disease activity, assessed using the British Isles Lupus Assessment Group (BILAG) index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Blood samples of 56 matched healthy individuals were obtained as controls for immunobiological outcomes monitored at each visit. The primary efficacy endpoint was assessed in all patients who completed 12 months of treatment, and all patients who received at least one dose of treatment were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT00779194. Findings Between March 9, 2009, and Dec 8, 2014, 43 patients were enrolled, three of whom did not meet eligibility criteria. 11 of the 40 eligible patients discontinued study treatment because of intolerance (n=2) or non-compliance (n=9). SLEDAI and BILAG disease activity scores were reduced during 12 months of treatment in 16 (55%) of 29 patients who completed treatment. Mean SLEDAI score decreased from 10·2 (SD 5·6) at enrolment to 4·8 (4·5) after 12 months of treatment (p + CD25 + FoxP3 + regulatory T cells and CD8 + memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4 + and CD4 − CD8 − double-negative T cells after 12 months. CD8 + memory T cells were selectively expanded in SRI-responders. Patient liver function and lymphocyte counts were unchanged. Although HDL-cholesterol ( Z = –2·50, p=0·012), neutrophil counts ( Z = –1·92, p=0·054), and haemoglobin ( Z = –2·83, p=0·005) were moderately reduced during treatment, all changes occurred within a range that was considered safe. Platelet counts were slightly elevated during treatment ( Z = 2·06, p=0·0400). Interpretation These data show that a progressive improvement in disease activity is associated with correction of pro-


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기